Last reviewed · How we verify

NCT06917378

TRIO CTO (Taiwan Research Initiative on Coronary Total Occlusion)

Recruiting now Last updated 18 December 2025
What this trial tests

trial testing Percutaneous coronary intervention of coronary chronic total occlusion in Chronic Total Occlusion (CTO) in 5,000 participants. Currently enrolling.

Timeline
1 January 2017
Primary endpoint
31 December 2034
31 December 2034

Quick facts

Lead sponsorNational Taiwan University Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment5,000
Start date1 January 2017
Primary completion31 December 2034
Estimated completion31 December 2034
Sites3 locations across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

National Taiwan University Hospital

Who can join

Adults 20 to 120, any sex, with Chronic Total Occlusion (CTO). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Coronary chronic total occlusions (CTO) present a significant challenge in the field of interventional cardiology. These complex lesions, characterized by complete blockage of a coronary artery for a prolonged duration, often require specialized techniques and strategies to achieve successful revascularization.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Chronic Total Occlusion (CTO)

Currently open trials in the same condition.

Other National Taiwan University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06917378.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing